On November 28th, the Penn Science Policy and Diplomacy Group was thrilled to welcome distinguished speaker Milan Yager, the Executive Director of the American Institute for Medical and Biological Engineering, to the University of Pennsylvania. His topic: Falling Out of Love with Science-- Why Congress Doesn't Fund Medical Innovation. Attendees heard about all the many innovations we use every day which were only made possible through generous federal funding for scientific research, from GPS technology to the iPhone screen. Mr. Yager also discussed the divide between many American voters and the scientists toiling away in their labs, as well as how to bridge the gap between the two seemingly very different worlds. Spoiler alert: the key is seeing the humanity in all people and taking time to understand each person's circumstances before casting aspersions on their opinions of things that might matter greatly to YOU but not to them.
Ian interviews Molly Sheehan, postdoctoral fellow at the University of Pennsylvania's department of bioengineering, and candidate for Pennsylvania's 7th Congressional District.
I chat with Molly about what it's like to run for office while still working in the lab and being a mother, her experiences so far on the campaign, what got her into politics, and her suggestions for college, graduate or medical students - or other postdocs - who are interested in getting politically engaged, but don't know where to start. Primary elections are on May 15th, 2018General elections are on November 6th, 2018If you're interested in volunteering for her, visit: mollysheehan.org/contact/
by Adrian Rivera-Reyes and Koreana Pak Soft
tissue sarcomas (STS) are rare cancers of the connective tissues, such as bone,
muscle, fat, and blood vessels. Soft and elastic, sarcoma tumors can push
against their surroundings as they grow silent and undetected. Residing in an
arm, torso, or thigh, it can take years before a sarcoma begins to cause pain.
By the time a patient presents their tumor to a doctor, amputation may be unavoidable1. In
2017, it is predicted that 12,390 Americans will be diagnosed with sarcoma, and
approximately 5,000 patients will die from these tumors2. But the
vast majority of these patients aren’t dying from the first tumor in their arm
or leg—the real danger is metastasis, which is responsible for more than 90% of
cancer-related deaths3-5. Metastasis
occurs when tumor cells leave their original site and colonize a new area of
the body, such as the lungs, liver, or bones3-5. The current treatment
options for sarcoma—surgery, chemotherapy, and radiation—are not v…